skip to main
|
skip to sidebar
Pharmalyst (Pharmalyst@gmail.com)
Friday, May 18, 2007
Chantix Pricing in China: Pharmalyst Reports....
....You decide by taking the poll at the end of the post.
Hat Tip:
Pharmagossip
for link to survey widget.
Data Sources:
1.
WHO Tobacco Atlas
2.
UN Human Development Index 2006
Thanks!!
0 comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
About Me
Pharmalyst
View my complete profile
Blog Archive
▼
2007
(82)
►
November
(1)
Pharmalyst RIP
►
October
(9)
Sanofi Ad: Please dump your Januvia etc and take o...
ExHubris: Post game analysis
Bong hits for Pfizer!
Yo Pfizer! You talking to moi?
The Cluster**** at Pfizer R&D
PharmaFraud hits his stride
Isentress Pricing: $10K a year
The secret plan of Andrew Witty?
Option traders betting on BMS takeover/merger?
►
September
(6)
Pfizer gets some adult supervision
Sanofi opens the R&D kimono
Chantix's Foibles
Isentress (Raltegravir) Pricing
Pharma Sector - In Private Equity's Crosshairs?
Chantix/Champix - International Pricing & PR Scams...
►
August
(8)
Medical financing: Subprime loans part deux?
Pfizer + Wyeth = ?
At least the PR arm is working well at Astra Zenec...
Novartis, Glivec & the Indian Patent Board: Curry ...
Can't build a better mousetrap in India?
Has Pfizer lost its marketing mojo?
Rheoscience & Dr. Reddy's: Brass Cojones?
Lilly, Pfizer: The new "Pet shop buys"
►
July
(8)
PharmaFraud comments on Pharmalyst among others
Alcohol addiction market
Earnings Season
Rivaroxaban, Apixaban - Meeting unmet needs and pr...
Erratic posting warning
Making of a quiet blockbuster - New Indications?
PAH drug pricing - update
Lovenox's rear view mirror - "Warning: Objects are...
►
June
(11)
Prospects for Oral Factor Xa Inhibitors Rivaroxaba...
Spirit makers take a page from big pharma's DTC ad...
Dr. John LaMattina's view of PFE stock
PAH Drug Pricing
GSK Consumer Division Sell Off?
Phat Phighting with PharmaGossip
Christopher Lydon talks to Dr. Marcia Angell
Maraviroc - "to be formally approved by the FDA on...
JNJ's Dapoxetine
CFO Exodus
Novartis share of hypertension market
▼
May
(10)
Pfizer and GSK shares can only go up from here?
End of the evergreening trend? WSJ blog handicaps ...
Chantix Pricing in China
Chantix Pricing in China: Pharmalyst Reports....
End of the "evergreening" trend?
Chantix/Champix - Developed country sales
Purdue Pharma - A pusher of another kind
NYT: Psychiatrists, Children and Drug Industry’s R...
The making of a quiet blockbuster - Update
The case for debt
►
April
(24)
►
March
(5)
Links
Brandweek NRx
Clinical Psyc
Dr. Peter Rost
Drug Watcher
E-Drug Search Blog
Healthy Skepticism
In the pipeline
IN VIVO Blog
Online Prescriptions
Pfizer Sales Representative Bill of Rights
Pharma Marketing Blog
Pharma's cutting edge
PharmaFraud
PharmaGiles
PharmaGossip
Pharmalot
PharmedOut
Prescription Access Litigation
Scientific Misconduct
The numbers guy
WSJ Health Blog
0 comments:
Post a Comment